
- /
- Supported exchanges
- / US
- / CGEM.NASDAQ
Cullinan Oncology LLC (CGEM NASDAQ) stock market data APIs
Cullinan Oncology LLC Financial Data Overview
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cullinan Oncology LLC data using free add-ons & libraries
Get Cullinan Oncology LLC Fundamental Data
Cullinan Oncology LLC Fundamental data includes:
- Net Revenue:
- EBITDA: -208 620 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.99
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cullinan Oncology LLC News

Disc Medicine Appoints Nadim Ahmed to its Board of Directors
Disc Medicine Inc WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerci...


InvestingPro's Fair Value model predicted CGEM's significant price correction
Investing.com’s Fair Value analysis has once again demonstrated its effectiveness in identifying mispriced stocks, as evidenced by Cullinan Oncology’s (NASDAQ:CGEM) significant price movement sinc...

Cullinan Oncology stock rating reiterated at Buy by Clear Street
Investing.com - Clear Street has reiterated its Buy rating and $22.00 price target on Cullinan Oncology Inc. (NASDAQ:CGEM), following the recent approval of a competing drug. The stock, currently trad...

Cullinan Therapeutics in-pact with Genrix Bio for velinotamig
[Business agreement] mediaphotos/iStock via Getty Images Cullinan Therapeutics (NASDAQ:CGEM [https://seekingalpha.com/symbol/CGEM]) signed a deal with Genrix Bio for an exclusive license for velinota...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.